ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0445

Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Abstract Number: 0446

Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Abstract Number: 0447

Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Abstract Number: 0448

A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities
Abstract Number: 0449

Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects
Abstract Number: 0450

Knowledge, Attitudes, and Intention Towards HPV Vaccination Among Reproductive-Age Women with Rheumatic Diseases
Abstract Number: 0451

Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
Abstract Number: 0452

Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study
Abstract Number: 0453

Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
Abstract Number: 0454

Evaluating the Rate of Cervical Cancer Screening and HPV Vaccination in Women with Systemic Lupus Erythematosus Within a Large Urban Healthcare System
Abstract Number: 0455

Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project
Abstract Number: 0456

Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Abstract Number: 0457

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Abstract Number: 0458

Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Abstract Number: 0459

Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].